Home / Deep Research / Agenesis of the Corpus Callosum with Peripheral Neuropathy

Agenesis of the Corpus Callosum with Peripheral Neuropathy

Agenesis of the Corpus Callosum with Peripheral Neuropathy Deep Research Fallback

⚠️ Fallback MONDO:0000902

Agenesis of the Corpus Callosum with Peripheral Neuropathy Deep Research Fallback

Provider Attempts

  • 2026-05-05T06:00Z: timeout 900 just research-disorder falcon Agenesis_of_the_Corpus_Callosum_with_Peripheral_Neuropathy was terminated after approximately 12 minutes with no provider output or research artifact.
  • 2026-05-05T06:17Z: timeout 420 just research-disorder openai Agenesis_of_the_Corpus_Callosum_with_Peripheral_Neuropathy timed out with exit code 124 and produced no research artifact.

No provider-generated research artifact was available to integrate. Curation therefore proceeded from generated structured Orphanet evidence and fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • ORPHA:1496 structured record for disease definition, MONDO and OMIM exact mappings, autosomal recessive inheritance, prevalence, SLC12A6 gene association, onset, and HPO phenotype frequencies.
  • PMID:12368912 for the original SLC12A6/KCC3 disease-gene discovery and functional evidence that the founder truncated KCC3 protein is membrane expressed but nonfunctional.
  • PMID:20301546 for GeneReviews clinical characteristics, SLC12A6 diagnostic testing, progression, supportive management, surveillance, genetic counseling, and reproductive testing.
  • PMID:12838516 and PMID:16606917 for clinical-review and patient-series evidence of early-onset sensorimotor neuropathy, corpus callosum dysgenesis, and truncating or missense KCC3 variant associations.
  • PMID:20549748, PMID:27230413, PMID:28647557, and PMID:29366908 for mechanism evidence linking KCC3 loss to disturbed neuronal ion or volume homeostasis, peripheral nerve conduction defects, axonopathy, and activity-dependent neuromuscular junction pathology.
  • PMID:32765936 and PMID:39988558 for recent human clinical and functional reports supporting variable corpus callosum involvement and SLC12A6 variant effects on ion transport or cellular localization.

Curation Conclusions

The accepted disease model is biallelic SLC12A6 loss of KCC3 potassium-chloride cotransporter function. KCC3 dysfunction disrupts neuronal potassium/chloride transport and cell-volume homeostasis, leading to peripheral axonopathy, nerve conduction failure, and neuromuscular junction pathology that manifest as progressive sensorimotor neuropathy, hypotonia, areflexia, and amyotrophy. Human clinical and structured Orphanet evidence support variable corpus callosum dysgenesis, developmental delay or intellectual disability, seizures, EEG abnormalities, and less frequent craniofacial, ocular, and CNS structural findings. Management is supportive, with molecular SLC12A6 testing, brain MRI, nerve electrophysiology, EEG when indicated, physiotherapy, orthoses, multidisciplinary developmental and psychiatric support, and genetic counseling.